title: [An oligopeptide improves solubility of paclitaxel by non-covalent interaction].
abstract: Based on the principle of non-covalent interactions between oligopeptides and paclitaxel for improving the solubility of paclitaxel, an oligopeptide, N terminal-W(L)-FFGREKD-C terminal (W8), was designed and the solubilization effect of W8 on paclitaxel was detected through experiments. The binding efficiency and the possible optimal conformation were optimized by molecular docking program. The solubilization effect of W8 on paclitaxel was determined by RP-HPLC. And the solubilization mechanism of oligopeptide to paclitaxel was proposed at molecular level. It was indicated from the docking result that there existed pi-pi interactions and several hydrogen-bond interactions between the oligopeptide and paclitaxel. After being solubilized by the oligopeptide, the aqueous solubility of paclitaxel was increased to 28 times. This study provided basis for further research of the solubilization of paclitaxel by oligopeptide and confirmed a novel approach for the design of safe oligopeptide solubilizing excipient.
authors.affiliation: Shenyang Pharmaceutical University, Shenyang 110016, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Tao
authors.initials: T
authors.lastname: Guo
authors.forename: Jing-Wen
authors.initials: JW
authors.lastname: Ge
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Li
authors.forename: Xue-Jun
authors.initials: XJ
authors.lastname: Xu
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Sun
authors.forename: Ji-Wen
authors.initials: JW
authors.lastname: Zhang
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry*; D015195:Drug Design; D062105:Molecular Docking Simulation; D009842:Oligopeptides / Q000737:chemistry*; D017239:Paclitaxel / Q000737:chemistry*; D011485:Protein Binding; D012995:Solubility; D013696:Temperature
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D009842:Oligopeptides; D017239:Paclitaxel